Searchable abstracts of presentations at key conferences in endocrinology

ea0022p454 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Peptide receptor radionuclide therapy and NETs: how to select patients?

Ahluwalia Rupa , McKane Gail , Vora Jiten , Vinjamuri Sobhan

Neuroendocrine tumors (NETs) are rare tumours arising from the gastroenteropancreatic axis. They are slow growing and often metastatic. Diagnostic workup requires imaging; both anatomical (ultrasound, CT, MRI) and functional (somatostatin receptor scintigraphy, PET).NETs strongly express somatostatin receptors (SSTRs) of five different subtypes (SSTRs1–5) with SSTR2 being the most common. Some NETs reflect hyperactivity of the guanethidine pathway. ...

ea0087p2 | Poster Presentations | UKINETS2022

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Khan Mohid , Davies Louise , Back Melissa , Shah Tahir , Pritchard Mark , Cook Kathryn , Hull Diana , McKane Gail , Day Melissa , Grandoulier Anne-Sophie , Higgs Kate

Introduction: LAN, a somatostatin analogue, is a common first-line treatment for NETs. LAN comes as a pre-filled, ready-to-use syringe, administered every 4 weeks. In the UK, patients may receive LAN at home. The aim of PREF-NET was to generate real-world evidence describing patient’s experience of LAN administered in homecare and hospital settings, and the associated impact of treatment setting on other areas of patients’ lives.Methods: PREF-N...